Inventor · disambiguated record
Jiuyang Zhao
Also filed as: ZHAO JIUYANG
9 granted patents·2 pending applications·9 citations·filing 2017–2022
79Inventor score
Files withSHENZHEN TARGETRX INC11
Top patents by PatentIndex Score
11 records- 0188US11319317B2(Hetero)arylamide compound for inhibiting protein kinase activitySHENZHEN TARGETRX INC·Filed 2020·Granted May 3, 2022·2 cites·18 claims
- 0282US10995103B2Substituted boric acid compound, pharmaceutical composition comprising same, and application thereofSHENZHEN TARGETRX INC·Filed 2017·Granted May 4, 2021·2 cites·16 claims
- 0381US10875853B2(Hetero)arylamide compound for inhibiting protein kinase activitySHENZHEN TARGETRX INC·Filed 2018·Granted Dec 29, 2020·3 cites·8 claims
- 0475US11091462B2(Hetero)arylamide compound for inhibiting protein kinase activitySHENZHEN TARGETRX INC·Filed 2018·Granted Aug 17, 2021·2 cites·17 claims
- 0565US2022389038A1Antiviral nucleoside reverse transcriptase inhibitorSHENZHEN TARGETRX INC·Filed 2022·Application pending·0 cites
- 0657US11453672B2Substituted pyrazolo[1,5-a]pyrimidines as tropomyosin receptor kinase inhibitorsSHENZHEN TARGETRX INC·Filed 2018·Granted Sep 27, 2022·0 cites·10 claims
- 0755US11447512B2Antiviral nucleoside reverse transcriptase inhibitorSHENZHEN TARGETRX INC·Filed 2018·Granted Sep 20, 2022·0 cites·10 claims
- 0854US2023322717A1Solid form of pyrazine substituted nicotinamide, and preparation and use thereofSHENZHEN TARGETRX INC·Filed 2021·Application pending·0 cites
- 0950US11345703B2Substituted pyrazolo[1,5-a]pyrimidine macrocyclic compoundSHENZHEN TARGETRX INC·Filed 2019·Granted May 31, 2022·0 cites·14 claims
- 1046US11389463B2Antiviral nucleoside reverse transcriptase inhibitorSHENZHEN TARGETRX INC·Filed 2018·Granted Jul 19, 2022·0 cites·14 claims
- 1146US11358973B2Di(hetero)aryl macrocyclic compound for inhibiting protein kinase activitySHENZHEN TARGETRX INC·Filed 2019·Granted Jun 14, 2022·0 cites·12 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →